{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T22:52:45Z","timestamp":1775947965316,"version":"3.50.1"},"reference-count":22,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Studies evaluating the incidence of infections after belatacept as a substitute for calcineurin inhibitors (CNI) or antimetabolite in kidney transplant (KT) yielded conflicting results. We compared infectious outcomes after belatacept\u2010use to no belatacept\u2010use in KT recipients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We included patients with primary KT between January 1, 2018, and December 31, 2022. We compared outcomes between those who received belatacept and those who did not. Cox proportional hazards models were used with belatacept as a time\u2010varying covariate and adjusted for gender, age at transplant, donor type, underlying disease, CMV serostatus, and organ transplant type. Anderson\u2010Gill hazard of the first Cox models was used to examine the recurrence of DNAemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 401 KT recipients, 25 received belatacept. Belatacept\u2010use had a higher hazard for EBV and CMV first infection (3.71 [95% CI 1.57, 8.72;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.003] and 2.63 [95% CI 1.04, 6.70;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.042], respectively), and for allograft failure (14.5 [95% CI 5.15, 41.0;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.001]) and acute cellular rejection (5.08 [95% CI 2.56, 11.5;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.001]). Each year increase in zage had a higher hazard for first EBV (3.71 [1.01, 1.05];\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.005) and CMV infection (1.02 [1.00, 1.04];\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.019). D+\/R\u2212 CMV serostatus had a higher hazard for first CMV infection relative to other serostatuses (4.96 [3.14, 7.85];\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Careful selection of KT for belatacept\u2010use is recommended in older recipients (\u2265\u00a055 years) due to the increased hazard of mortality, CMV, and EBV DNAemia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/tid.70175","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T10:51:46Z","timestamp":1769424706000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Role of Belatacept\u2010Use and Senescence on Infectious and Mortality Complications After Kidney Transplantation"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3788-7763","authenticated-orcid":false,"given":"Hareesh","family":"Singam","sequence":"first","affiliation":[{"name":"Department of Infectious Disease Cleveland Clinic Foundation Cleveland Ohio USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8329-9842","authenticated-orcid":false,"given":"Abdinoor","family":"Abdi","sequence":"additional","affiliation":[{"name":"University of Minnesota Medical School  Minneapolis Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5178-4481","authenticated-orcid":false,"given":"Wyatt","family":"Tarter","sequence":"additional","affiliation":[{"name":"Medtronic  Minneapolis Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6735-3853","authenticated-orcid":false,"given":"Ben","family":"Langworthy","sequence":"additional","affiliation":[{"name":"Division of Biostatistics &amp; Health Data Science University of Minnesota  Minneapolis Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7337-5681","authenticated-orcid":false,"given":"Adam","family":"Bregman","sequence":"additional","affiliation":[{"name":"Division of Nephrology University of Wisconsin  Madison Wisconsin USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4131-647X","authenticated-orcid":false,"given":"Karam M.","family":"Obeid","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and International Medicine University of Minnesota  Minneapolis Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,1,26]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2010.03016.x"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.03005.x"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12459"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12460"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12810"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13830"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2021050628"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2012.01535.x"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2016.09.021"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8081164"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16132"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16430"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfz255"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2016.05.017"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-15-1045-8_9"},{"issue":"3","key":"e_1_2_9_17_1","first-page":"212","article-title":"Prospective Monitoring of Cytomegalovirus, Epstein\u2010Barr Virus, BK Virus, and JC Virus Infections on Belatacept Therapy After a Kidney Transplant","volume":"12","author":"Bassil N.","year":"2014","journal-title":"Experimental and Clinical Transplantation"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16430"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/15269248221122894"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajt.2024.09.035"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.15171\/jnp.2016.15"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13516"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.03005.x"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.70175","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/tid.70175","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.70175","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T22:41:31Z","timestamp":1775947291000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.70175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1111\/tid.70175"],"URL":"https:\/\/doi.org\/10.1111\/tid.70175","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,26]]},"assertion":[{"value":"2025-10-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70175"}}